1. In Vivo
  2. >>Business Strategy

Can MDCO Make Alnylam’s PCSK9 Candidate Work In The Hospital?

Lagging the antibodies in the PCSK9 race, MDCO’s candidate brings certain strengths, not the least being a fundamentally different mechanism. But where the big boys will target larger populations in multiple settings, MDCO is hunkering down in the channel it knows best – the hospital cath lab – counting on changing practice behavior to speed its uptake.

With only early-stage data in hand, The Medicines Co.’s (MDCO) PCSK9 candidate, the centerpiece of its budding lipid franchise, is far behind competitors. But MDCO is counting on a highly differentiated technology, as well as changing practice patterns among interventional cardiologists to help bolster the drug’s uptake. And its last-to-market position may enable it to take optimal advantage of evolving cholesterol management guidelines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

 
• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

Biotech Leaders Ponder Trump’s Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.